Bringing science and development together through news and analysis

  • US drug policy 'hinders major HIV drug trial'


A major international clinical trial of HIV drugs is failing to recruit patients from developing countries because of US opposition to generic drugs, say critics. The US$120 million Strategies for Management of Anti-Retroviral Therapy (SMART) trial is funded by the US National Institute of Allergy and Infectious Diseases (NIAID). The institute requires that only participants taking drugs approved by the US Food and Drug Administration can enrol in the trial.

The SMART trial aims to enrol 6,000 patients, but those in Argentina, Brazil, Peru and Thailand have been unable to take part because they are taking generic versions of brand-name anti-retroviral drugs. So far, only 792 of the 2,264 patients who were expected to enrol in the trial this year have done so. Recruiting from the trial's Latin American and Thai wings would add 733 more patients.

The head of NIAID, Anthony Fauci, says there is no policy to exclude generic drugs from international trials. But activists believe that a desire to protect the market share of US companies producing the brand-name drugs is to blame for the trial's slow start.

Link to full Nature news story

Reference: Nature 431, 493 (2004)

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.